1. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
- Author
-
Alice M, Jackson, Rasmus, Rørth, Jiankang, Liu, Søren Lund, Kristensen, Inder S, Anand, Brian L, Claggett, John G F, Cleland, Vijay K, Chopra, Akshay S, Desai, Junbo, Ge, Jianjian, Gong, Carolyn S P, Lam, Martin P, Lefkowitz, Aldo P, Maggioni, Felipe, Martinez, Milton, Packer, Marc A, Pfeffer, Burkert, Pieske, Margaret M, Redfield, Adel R, Rizkala, Jean L, Rouleau, Petar M, Seferović, Jasper, Tromp, Dirk J, Van Veldhuisen, Mehmet B, Yilmaz, Faiez, Zannad, Michael R, Zile, Lars, Køber, Mark C, Petrie, Pardeep S, Jhund, Scott D, Solomon, John J V, McMurray, and Cardiovascular Centre (CVC)
- Subjects
Heart Failure ,Prediabetic State ,Natriuretic Peptide, Brain ,Diabetes Mellitus ,Humans ,Stroke Volume ,Middle Aged ,Prognosis ,Cardiology and Cardiovascular Medicine ,Peptide Fragments ,Ventricular Function, Left - Abstract
Aim: There is an association between heart failure with preserved ejection fraction (HFpEF) and insulin resistance, but less is known about the diabetic continuum, and in particular about pre-diabetes, in HFpEF. We examined characteristics and outcomes of participants with diabetes or pre-diabetes in PARAGON-HF.Methods and results: Patients aged ≥50 years with left ventricular ejection fraction ≥45%, structural heart disease and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) were eligible. Patients were classified according to glycated haemoglobin (HbA1c): (i) normal HbA1c, Conclusion: Pre-diabetes is common in patients with HFpEF and is associated with worse clinical status and greater risk of HFH. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT01920711.
- Published
- 2022